血清CA125水平与充血性心力衰竭关系初探

目的探讨充血性心力衰竭(CHF)患者血清中CA125水平与心功能的关系。方法169例CHF患者符合纽约心脏病学会心功能分级标准,分为心功能Ⅱ~Ⅳ级组,根据超声心动图检查结果,将入选者分为左心室(左室)正常组(左室舒张末期容积≤55 mm)和左室增大组(左室舒张末期容积>55 mm)。用免疫放射分析法测定血清CA125水平。并选择20名正常人作为对照组。结果CHF患者CA125血清浓度明显高于正常对照组(P<0.01),心功能Ⅲ、Ⅳ级的血清浓度高于Ⅱ级(P<0.01)。左室增大组较左室正常组CA125血清浓度显著升高(P<0.01),CA125的血清浓度与心力衰竭患者的CHF严重程度和心脏左室增大呈正相关(P<0.01)。结论CA125可能是又一个与CHF相关的非创伤性指标。     

慢性心力衰竭患者血清CA125水平检测及临床意义

目的 研究慢性心力衰竭(CHF)患者不同心功能状态下血清肿瘤抗原125(CA125)水平的改变及其临床意义.方法 对32例CHF患者按照纽约心功能分级标准分为心功能Ⅰ级和Ⅱ级组(A组)17例心功能Ⅲ级和Ⅳ级组(B组)15例,用化学发光法测定其血清CA125水平,并与25例健康人比较.结果 CHF患者血清CA125平均水平高于对照组(P<0.01),B组血清CA125平均水平高于A组.结论 血清CA125水平与CHF患者心功能相关,临床上观察CA125的水平变化可以作为评价CHF患者心功能的一个重要指标.     

血清糖类抗原125及血浆尿钠肽水平与充血性心力衰竭的关系

目的:探讨慢性充血性心力衰竭(CHF)患者糖类抗原125(CA125)及B型尿钠肽(BNP)水平与患者心功能及其相关因素之间的关系。方法:108例CHF患者通过B超测定左室内径及左室射血分数(LVEF),以酶联免疫吸附法(ELISA)测定其血清CA125水平,以BiositeTriage快速诊断仪测定其血浆BNP水平,所有患者根据纽约心功能分级标准分为Ⅱ、Ⅲ、Ⅳ级组。另随机抽取40例有心血管疾病但无CHF的患者作为非CHF组。结果:①CHF组血清CA125及BNP水平高于非CHF组,Ⅳ级心功能组水平明显高于Ⅲ级组,且Ⅲ级组明显高于Ⅱ级组;②血清CA125及BNP水平均与LVEF呈负相关,而与导致CHF的原发病种类不相关。结论:CHF患者血清CA125及BNP水平升高,并且其水平与LVEF有关,而与导致CHF的原发病种类无关。     

慢性心力衰竭患者血清CA125测定的临床意义

目的探讨慢性心力衰竭(CHF)患者血清糖类抗原125(CA125)与心功能之间的关系。方法 62例(男38例、女24例)CHF患者根据纽约心功能分级标准分为Ⅱ级、Ⅲ级、Ⅳ级组;根据左室射血分数(LVEF)值分为≥50%组、49%～35%组、≤35%组。另选正常对照组20例(男8例、女12例)。采用微粒子酶免疫化学发光法(META)测定血清CA125水平,超声心动图测定LVEF。结果 CHF患者各组血清CA125水平随心功能恶化程度的增加而升高,心功能Ⅱ级为(22.84±11.48)U/mL,Ⅲ级为(50.65±26.88)U/mL,Ⅳ级为(185.46±105.60)U/mL,均较对照组(9.64±3.06)U/mL升高(P<0.05),各组间比较差异有统计学意义(P<0.05);随着LVEF的降低,血清CA125水平升高。结论慢性心力衰竭患者血清CA125升高,其变化程度对评价心功能程度有一定的参考价值。     

血清糖类抗原125及心肌肌钙蛋白I水平与扩张型心肌病并慢性充血性心力衰竭患者心功能的相关性研究

目的分析血清糖类抗原125(CA125)、心肌肌钙蛋白I(cTnI)水平与扩张型心肌病(DCM)并慢性充血性心力衰竭(CHF)患者心功能的相关性。方法选取2015年2月—2016年2月广西壮族自治区来宾市中医医院收治的DCM并CHF患者98例作为A组,选取同期收治的单纯DCM患者96例作为B组,另选取同期体检健康者96例作为对照组;参照美国纽约心脏病协会(NYHA)心功能分级标准将DCM并CHF患者分为Ⅰ级22例、Ⅱ级24例、Ⅲ级25例、Ⅳ级27例。比较3组受试者及不同心功能分级DCM并CHF患者血清CA125、cTnI水平,并分析血清CA125、cTnI水平与DCM并CHF患者心功能分级的相关性。结果 A组和B组患者血清CA125、cTnI水平高于对照组,A组患者血清CA125、cTnI水平高于B组(P0.05)。心功能分级Ⅱ级、Ⅲ级、Ⅳ级患者血清CA125、cTnI水平高于Ⅰ级患者,Ⅲ级、Ⅳ级患者血清CA125、cTnI水平高于Ⅱ级患者,Ⅳ级患者血清CA125、cTnI水平高于Ⅲ级患者(P0.05)。Spearman秩相关性分析结果显示,血清CA125、cTnI水平与心功能分级呈正相关(rs分别为0.829、0.453,P0.05)。结论血清CA125、cTnI水平与DCM并CHF患者心功能分级呈正相关。     

CAl25和肿瘤坏死因子α的血清浓度与慢性充血性心力衰竭相关性的临床研究

目的探讨慢性充血性心力衰竭(CHF)患者血清中CA125和肿瘤坏死因子α(TNFα)的浓度与心功能和心脏扩大的关系.方法 102例心力衰竭患者根据纽约心脏病学会心功能分级标准分为心功能Ⅱ～Ⅳ级组,根据超声心动图检查结果分为左室常大组(左室舒张末期容积≤55mm)和左室扩大组(左室舒张末期容积＞55mm).用酶联免疫吸附测定法测定CA125和TNFα的血清浓度.并选20名正常人作为对照.结果 CHF患者CA125和TNFα的浓度明显高于正常对照组(P＜0.晒～0.01),心功能Ⅲ、Ⅳ级的血清浓度高于Ⅱ级(P＜0.01).左室扩大组较左室常大组CA125和TNFα的血清浓度显著升高(P＜0.01),CA125和TNFα的血清浓度与心力衰竭患者的心脏扩大呈正相关(r=0.621及0.54,P＜0.05).结论 CHF患者血清中CA125和TNFα的血清浓度升高,升高水平与CHF患者心脏扩大呈正相关.     

CA125和肿瘤坏死因子α的血清浓度与慢性充血性心力衰竭相关的临床研究

目的探讨慢性充血性心力衰竭(CHF)患者血清中CA125和肿瘤坏死因子α(TNFα)的浓度与心功能和心脏扩大的关系.方法 102例心力衰竭患者根据纽约心脏病学会心功能分级标准分为心功能Ⅱ～Ⅳ级组,根据超声心动图检查结果分为左室常大组(左室舒张末期容积≤55mm)和左室扩大组(左室舒张末期容积＞55mm).用酶联免疫吸附测定法测定CA125和TNFα的血清浓度.并选20名正常人作为对照.结果 CHF患者CA125和TNFα的浓度明显高于正常对照组(P＜0.晒～0.01),心功能Ⅲ、Ⅳ级的血清浓度高于Ⅱ级(P＜0.01).左室扩大组较左室常大组CA125和TNFα的血清浓度显著升高(P＜0.01),CA125和TNFα的血清浓度与心力衰竭患者的心脏扩大呈正相关(r=0.621及0.54,P＜0.05).结论 CHF患者血清中CA125和TNFα的血清浓度升高,升高水平与CHF患者心脏扩大呈正相关.     

老年心力衰竭患者血清CA125、C反应蛋白水平变化

目的观察慢性心力衰竭(CHF)患者血清CA125、C反应蛋白(CRP)水平与心功能变化及左室舒张末期内径(LVEDd)之间的关系和临床意义。方法 74例CHF患者按NYHA分级标准分为心功能Ⅱ级、Ⅲ级、Ⅳ级组,测定入院时血清CA125、CRP水平及左室内径,其中有65例CHF患者于入院5～10天心力衰竭控制后复查了CA125及CRP。另随机抽取54例同期住院的心功能代偿的心血管病患者为对照组。采用SPSS13.0软件进行统计学分析,计量参数以(x±s)表示,组间比较用t检验,心力衰竭治疗前后用配对t检验。CA125、CRP与左室内径的关系采用直线相关分析。结果 (1)CHF组血清CA125及CRP水平明显高于对照组(P<0.01),Ⅳ级心功能组水平明显高于Ⅲ级组,Ⅲ级组明显高于Ⅱ级组;治疗后CA125及CRP水平随心衰好转而显著下降(P<0.01)。(2)血清CA125及CRP浓度的升高与LVDd的大小呈正相关(r=0.58及0.53,P相似文献   

慢性充血性心力衰竭病人血清心肌肌钙蛋白T浓度的变化及临床意义

目的观察慢性充血性心力衰竭(CHF)病人血清心肌肌钙蛋白T(cTnT)水平是否升高.方法应用酶联免疫吸附分析法检测190例CHF病人(心力衰竭组)和75名健康人(对照组)血清cTnT.结果心力衰竭组cTnT浓度为0.23±0.17 ng/ml,对照组cTnT浓度为0.03±0.01 ng/ml,两组比较有非常显著差异(P<0.01).105例病人左心室射血分数(LVEF)≤0.35,其血清cTnT浓度为0.31±0.22 ng/ml;85例病人LVEF>0.35,其血清cTnT浓度为0.13±0.07 ng/ml,二者比较有非常显著性差异(P<0.01).心功能分别为Ⅱ、Ⅲ、Ⅳ级(NYHA)的病人,其血清cTnT浓度分别为0.11±0.10 ng/ml、0.19±0.20 ng/ml、0.38±0.21 ng/ml(Ⅱ级与Ⅲ级相比、Ⅲ级与Ⅳ级相比均有非常显著差异,P<0.01).血清中的心肌cTnT浓度与左心室射血分数成负相关(γ=-0.493,P<0.001).结论CHF病人血清cTnT浓度升高,其升高程度和心力衰竭严重程度相平行.     

血清肿瘤抗原CA125水平与慢性心力衰竭关系的初步探讨

目的:探讨慢性心力衰竭(CHF)患者肿瘤抗原CA125(简称CA125)水平与患者心功能之间的关系。方法:108例CHF患者通过B型超声心动图测定左心室内径及射血分数并探察是否有胸腔积液,以酶联免疫吸附法测定其血清CA125水平,所有病例根据纽约心功能分级标准分为Ⅱ、Ⅲ、Ⅳ级组,根据有无胸腔积液而分为胸腔积液患者和非胸腔积液患者。另随机抽取40例有心血管疾病但无CHF的患者作为对照组。结果:CHF患者血清CA125水平高于对照组,Ⅳ级组血清CA125水平明显高于Ⅲ级组且Ⅲ级组明显高于Ⅱ级组,血清CA125水平与左心室射血分数值呈负相关,而与导致CHF的原发病种类不相关。胸腔积液患者血清CA125水平明显高于非胸腔积液患者,非胸腔积液患者明显高于对照组。结论:①CHF患者血清CA125水平升高,其水平与左心室射血分数呈负相关,而与导致CHF的原发病种类不相关;②胸腔积液患者其血清CA125水平高于非胸腔积液患者,这可能是由于胸膜间皮细胞分泌增加或胸腔积液刺激血清CA125的释放及阻碍其清除有关;③血清CA125水平的测定可能可以用来评价CHF治疗的疗效并可能用来评价预后。     

CA125和肿瘤坏死因子α的血清浓度与慢性充血性心力衰竭相关性的临床研究

目的　探讨慢性充血性心力衰竭 (CHF)患者血清中CA12 5和肿瘤坏死因子α(TNFα)的浓度与心功能和心脏扩大的关系。方法　 10 2例心力衰竭患者根据纽约心脏病学会心功能分级标准分为心功能Ⅱ～Ⅳ级组 ,根据超声心动图检查结果分为左室常大组 (左室舒张末期容积≤ 5 5mm)和左室扩大组 (左室舒张末期容积 >5 5mm)。用酶联免疫吸附测定法测定CA12 5和TNFα的血清浓度。并选 2 0名正常人作为对照。结果　CHF患者CA12 5和TNFα的浓度明显高于正常对照组 (P<0 .0 5 ～ 0 .0 1) ,心功能Ⅲ、Ⅳ级的血清浓度高于Ⅱ级 (P <0 .0 1)。左室扩大组较左室常大组CA12 5和TNFα的血清浓度显著升高 (P <0 .0 1) ,CA12 5和TNFα的血清浓度与心力衰竭患者的心脏扩大呈正相关 (r=0 .6 2 1及 0 .5 4,P <0 .0 5 )。结论　CHF患者血清中CA12 5和TNFα的血清浓度升高 ,升高水平与CHF患者心脏扩大呈正相关。     

老年男性充血性心力衰竭患者血清肿瘤相关抗原125水平与心功能的关系

目的 探讨老年充血性心力衰竭(CHF)患者血清肿瘤相关抗原125(CA125)水平与心功能等相关因素间的关系.方法 测定152例老年CHF患者血清肿瘤标志物CA125、癌胚抗原(CEA)、甲胎蛋白(AFP)、CA199、CA15-3和CA724,以及血清肌酐(Cr)、尿素氮(BUN)、尿酸(UA)、丙氨酸氨基转移酶(A...     

慢性心力衰竭患者CA125和TNF-α水平的变化及临床意义

目的 探讨慢性心力衰竭患者血清糖类抗原-125（CA125）、肿瘤坏死因子-α（TNF-α）水平与心功能及结构的关系.方法 收集慢性心力衰竭（CHF）患者128例作为观察组,按NYHA标准分为心功能Ⅱ级、Ⅲ级、Ⅳ级.另选同期健康体检者42名作为对照组.采用微粒子酶联免疫化学发光法检测所有患者血清CA125浓度,酶联免疫法（ELISA）测定TNF-α浓度,同时采用彩色多普勒超声诊断仪测定左心室射血分数（LVEF）和左心室舒张末期内径（LVEDD）.结果 ①与对照组比较,不同心功能分级CHF患者TNF-α、CA125及LVEDD明显升高,LVEF明显降低,差异均有统计学意义（P＜0.05）,且TNF-α和CA125水平随心功能分级增高而升高.治疗后TNF-α与CA125水平随心衰控制好转而显著下降,LVEF随心衰控制好转而显著上升.②CA125、TNF-α与LVEF呈负相关,与LVEDD呈正相关（P＜0.05）.③不同病因慢性心力衰竭患者血清中TNF-α水平差异无统计学意义;CA125水平差异有统计学意义,且其浓度在扩张型心肌病＞冠心病＞高血压心脏病＞风湿性心脏病.结论 慢性心力衰竭患者血清中CA125和TNF-α水平高,并可作为反映心力衰竭诊断严重程度的辅助指标.     

N端脑钠肽前体对老年慢性心力衰竭的诊断价值

目的探讨老年慢性心力衰竭（CHF）患者血浆脑钠肽前体（NT-proBNP）水平与左室功能的关系及临床意义。方法将93例老年CHF患者按美国心脏病协会（NYHA）分级方法分为心功能Ⅱ、Ⅲ、Ⅳ级3组,25名健康老年人纳入对照组。采用电化学发光免疫分析技术测定4组血浆NT-proBNP水平,用超声心动图测定左室舒张末期内径（LVEDD）和左心室射血分数（LVEF）。结果心力衰竭NT-proBNP、LVEDD显著高于对照组（P〈0.01）,且血清NT-proBNP浓度随着心功能分级的增加而升高（3组两两比较均有统计学意义,P〈0.01）。NT-proBNP水平与LVEDD呈正相关（r=0.711,P〈0.01）,而与LVEF呈负相关（r=-0.85,P〈0.01）。结论血浆NT-proBNP水平可作为CHF患者心功能检测的有效生化指标,可以用来评估老年心力衰竭患者的左室功能。     

Serum levels of different tumour markers in patients with chronic heart failure

BACKGROUND: serum levels of carbohydratic antigen 125 (CA 125), a tumour marker related to ovarian cancer, are increased in patients with heart failure (CHF). To our knowledge there are no data concerning the levels of other tumour markers in CHF. METHODS: we measured serum levels of Alpha-Fetoprotein (AFP), Carcinoembrionic antigen (CEA), CA 19.9, CA 15.3 and CA 125, in 191 pts (86 males, mean age 67+/-10 years) with mild to severe CHF due to left ventricular systolic dysfunction. RESULTS: Only CA-125 was increased in CHF patients: mean values were significantly higher (P<0.05) in NYHA classes III (60+/-22 UI/ml) and IV (192+/-115 UI/ml) compared to NYHA class I-II patients (16+/-11). Mean values of the other tumor markers were within the normal range. AFP was above the upper normal limit in 2/191 patients (1%), CEA in 5/191 (2.6%), CA 19.9 in 0, CA 15.3 in 2/191 (1%) and CA 125 in 126/191 patients (66%). In 30 NYHA IV patients, tumour markers were repeated after 5-20 days of aggressive medical treatment, when a clinical improvement (reduction of at least 1 NYHA class) was reached: mean serum levels of CA 125 decreased from 107+/-85 to 19+/-8 U/ml (P<0.05); no changes in other tumour markers were observed. CONCLUSIONS: Of the tumour markers evaluated, only CA 125 seems to be related to the presence and severity of CHF and shows significant changes in response to medical therapy. The biologic and clinical relevance of this observation needs to be defined.     

The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters

OBJECTIVE: To assess serum levels of carbohydrate antigen 125 (CA125) in patients with chronic congestive heart failure (CHF) and to assess any correlation with clinical symptoms and echocardiographic indices. PATIENTS AND METHODS: We enrolled 77 male patients (mean age: 73+/-10 years) admitted to the Cardiology Emergency Department (ED) with cardiac symptoms requiring hospitalization. Diagnosis of CHF was based upon medical history or initial echocardiographic evaluation on current admission. Serum CA125 was measured by an enzyme immunoradiometric assay, on admission and before discharge. RESULTS: The median overall CA125 value was 22.4 (11.5-48.9) U/ml. Serum CA125 levels were related to the severity of CHF [New York Heart Association (NYHA) class I: 19.2 (7.2-31) U/ml, NYHA class II: 17.6 (10-23) U/ml, NYHA class III: 32 (25-77) U/ml and NYHA class IV: 34.3 (18.6-77) U/ml (p<0.04)]. Patients in NYHA classes III and IV had significantly higher mean values of CA125, than patients in class II (p<0.005 and p<0.05, respectively). Moreover, patients with fluid congestion (pulmonary congestion, ankle edema) had higher levels of serum CA125 than patients without congestion (p=0.002 and p<0.03, respectively). Finally, levels of serum CA125 correlated weakly with right ventricular systolic pressure (RVSP) and renal function, while no significant correlation was found between CA125 and E wave deceleration time on Doppler echocardiography, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), liver function and the medical treatment prescribed. CONCLUSION: Serum CA125 is associated with the clinical severity of CHF and the symptoms and signs of fluid congestion and therefore may be a useful additional tool for the evaluation and clinical staging of these patients.     

半胱氨酸蛋白酶抑制物C在心力衰竭的临床意义

目的观察慢性心力衰竭患者血清半胱氨酸蛋白酶抑制物C的变化及其临床意义。方法心力衰竭60例．心功能正常对照患者30例，测定半胱氨酸蛋白酶抑制物C、血肌酐、血尿素氮、血尿酸浓度，与左心室射血分数、左心室舒张末内径进行相关分析，并随访半年。结果半胱氨酸蛋白酶抑制物C水平在血尿素氮、血肌酐、血尿酸正常的心力衰竭患者高于对照组（P〈O．01），与左心室射血分数呈负相关（r=--O．288，P〈O．05），与左心室舒张末内径呈正相关（r=O．561，P〈O．01）；在心力衰竭患者中，半胱氨酸蛋白酶抑制物C大于1mg／L病人因心力衰竭加重而再住院率明显高于半胱氨酸蛋白酶抑制物C不大于1mg／L病人（P=0．039）。结论无原发性肾脏病变的心力衰竭患者存在早期的肾功能异常，半胱氨酸蛋白酶抑制物C不但是反映心力衰竭患者早期肾功能损伤的敏感指标，而且也是心力衰竭患者预后的重要危险因素。     

不同病因对老年心力衰竭患者血清CA125水平的影响

目的 研究不同病因所致老年心力衰竭患者CA125的变化情况,探讨与血B型脑钠肽(BNP)间的关系.方法 155例确诊的慢性心力衰竭患者,按照纽约心脏学会(NYHA)心功能分级Ⅲ级或Ⅳ级的老年患者作为研究对象,根据患者病因分为高血压组、冠心病组、心肌病组及其他病因组,选取25例健康体检老年人为对照组;采用化学免疫发光法定量测定血清CA 125值,采用微粒子酶联免疫检测法定量测定血浆BNP水平,将各组间的CA 125值进行比较,并对CA 125与BNP间的相关性进行分析.结果 高血压组、冠心病组、心肌病组及其他病因组血清CA125值分别为(83.4±6.6)U/L、(36.8±1.4) U/L、(38.1±1.6)U/L及(38.4±1.4)U/L,高于对照组(14.3±1.15)U/L,差异有统计学意义(均P＜0.05);其中高血压组CA125值高于其他各组(P＜0.05),且与BNP呈正相关(r=0.67,P＜0.05).结论 CA 125值可作为诊断心力衰竭的筛选指标,且对评价引起心力衰竭的病因有一定的预测价值.

Abstract：

Objective To investigate the effect of different etiology on the serum level of carbohydrate antigen 125 (CA125) in elderly patients with chronic congestive heart failure (CHF), and to assess any correlation of CA125 with serum level of B-type natriuretic peptide (BNP). Methods The 155 aged patients with New York Heart Association (NYHA) class Ⅲ or Ⅳ were enrolled and grouped into four reasons of hypertension, coronary heart disease (CHD), cardiomyopathy and other reasons, and 25 healthy old persons as control.CA125 and BNP levels were measured by automatic chemiluminescent immunoassay and enzyme immunoradiometric assay, respectively. Results CA125 level in patients with CHF was (83.4±6.6)U/L for hypertension, (36.8±1.4)U/L for CHD, (38.1±1.6)U/L for cardiomyopathy and (38.4±1.4)U/L for other reasons, which significantly higher than for healthy controls [(14.3±1.15) U/L, P＜0.05].Especially, CA125 level in hypertension group was notable higher than in other reasons of group (P＜0.05), and was positively related to BNP level (r=0.67,P＜0.05). Conclusions Serum CA125 level is a predictor for clinical pathogen of CHF.Therefore, it may be a useful additional marker for the evaluation of clinical treatment of these patients